NorthWest Biotherapeutics Inc (NWBO)

[IkeEsq]

RE: hoffmann6383 -

There is a large drumbeat on these forums that if NWBO doesn't present at the Society for Neuro-Oncology (SNO) the data is somehow bad, the management is poor, the management doesn't know what they are doing if the release of the TLD doesn't coincide with a presentation at a major conference, etc. It is setting up a BIG LET DOWN and giving bears ammo for more forum fodder/spam.

I tried to caution people here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166632621 and have done so in the past. As you suggest, people are trying to bend the information we have to fit what they want to happen and it is likely to just lead to increasing disappointment if it does not happen. So in answer to your question: No, there is nothing to suggest that NWBO will present at SNO.

As you point out, late-breaking abstracts do not appear to be designed for what NWBO has to offer. TLD has been available for a year. The thought is that using late-breaking abstracts, the company can keep everything a surprise so that they can 'own the shorts' or something. Why you would want a company to delay publication of TLD on the off-chance of catching some short sellers is a mystery.

The sad thing is that there are an awful lot of people who seem to think that they are in a better position to judge the appropriate time and method of data release than the people who have been: A) running this trial for over a decade; B) in possession of the actual unblinded data; C) advised by a Scientific Advisor Board made up of top people in the field; D) in talks with the regulators; E) dealing with medical journals and knowledgeable about the status of the publication; F) familiar with current production capacity and future expansion of same; G) aware of current financial position, burn rate, amount of income now and projected, financing opportunities; etc. It is really a shocking display of hubris.

To quote Linda Powers from 2019: (https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146542058)

"ASCO is certainly a great venue and it's been great for us when the timing has worked out, to be able to, as we did last year we had just announced the first interim data from our phase III trial, three days before ASCO, that just happened to work out beautifully on the timing. And a few years before that we had unveiled our initial DC Vax-Direct data. So we agree with you that it's great when that works."

So they are not going to wait on a major conference, they are going to release the data when they are ready and if it works out that that time is at or around a major conference, great.